Latest news with #CRC
Business Wire
22 minutes ago
- Health
- Business Wire
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more pleasant new option for CRC screening for eligible individuals 45+. 'I was relieved to learn about Guardant's Shield blood test because it's a more pleasant and convenient way to get screened, especially for those who've been hesitating.' Known for iconic roles in Varsity Blues, Rules of Attraction and Don't Trust the B in Apartment 23, Van Der Beek has created many memorable characters in his 20+-year TV and film career, both on screen and as a producer, director and writer. Van Der Beek went public with his CRC diagnosis in November 2024 to encourage others to take control of their health. Today marks the first time he is speaking out about the critical importance of staying up to date with CRC screening guidelines. 'I was 46 years old, in great physical shape, and had no idea I was living with stage 3 colorectal cancer. It's the second most deadly cancer, but the most curable when caught in its early stages, making screening crucial,' said Van Der Beek. 'I was relieved to learn about Guardant's Shield blood test because it's a more pleasant and convenient way to get screened, especially for those who've been hesitating. I've learned a lot on my cancer journey, but I wouldn't wish this on anyone. Simply put, getting screened can save your life. If you're 45 or older, make sure you talk to your doctor about screening guidelines and your options.' CRC is a significant health concern with over 50,000 Americans dying from the disease each year, making it the second most deadly cancer in the U.S. Early detection is crucial, as the five-year survival rate is over 90% when CRC is caught in its early stages, but plummets to 13% in late stages when symptoms usually appear. Despite these odds, more than 50 million people – one in three American adults age 45 and over – avoid screening in part because traditional methods are viewed as unpleasant or inconvenient. 'We are grateful to James for the work he has done to raise awareness with his personal story that shows the importance of screening and early detection,' said AmirAli Talasaz, Guardant Health co-CEO. 'Our goal is to ensure that everyone who should be screened for colorectal cancer gets screened – and the Shield blood test is a major step forward in making screening more convenient and accessible across the country. We are committed to saving lives through early detection and – with James' help – we hope more Americans are encouraged to take this critical step.' 'In my primary care practice, I'm on the frontlines of colorectal cancer and screenings are one of the best tools we have, helping us to catch and treat colorectal cancer at early stages,' said Dr. Angel Lazo, an internal medicine physician in New Jersey. 'In my practice, it can be difficult for patients to screen with traditional methods. Adding the option of Shield has made it much more convenient and expanded screening to more people, giving peace of mind to them – and to me as their doctor.' Shield is the first blood test approved by the U.S. Food and Drug Administration as a primary screening option for CRC. It is intended for adults age 45 and older at average risk for the disease and can be ordered by any prescribing healthcare provider. With Shield, individuals can undergo screening with a simple blood draw and results are typically available within two weeks. Recently, the National Comprehensive Cancer Network included the Shield blood test in its updated CRC screening guidelines, paving the way for improved patient access and additional major clinical guideline inclusions. For more information about the Shield blood test, visit About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Medscape
22 minutes ago
- Health
- Medscape
Patients With IBD and PSC Face Elevated CRC Risk
TOPLINE: Patients with inflammatory bowel disease (IBD), especially those who had been diagnosed before 20 years of age, and with primary sclerosing cholangitis (PSC) had an elevated risk for colorectal cancer (CRC). METHODOLOGY: Researchers conducted a cohort study to analyse the effect of IBD with and without PSC on the risk for CRC. They enrolled patients with IBD diagnosed between January 1969 and December 2014 from the Swedish National Patient Register, including those who underwent colectomy. Patients were classified as those having PSC on the basis of the diagnosis of cholangitis. A total of 85,813 patients with IBD alone and 3066 with IBD and concomitant PSC were included. Each patient with IBD was matched with five control individuals from the general population without IBD (n = 432,037). Information on the diagnosis of CRC and cause of death was obtained using register data. Synchronous cancer was defined as two or more CRCs occurring within or less than 180 days. TAKEAWAY: Patients with IBD and concomitant PSC and those without PSC had an increased risk for CRC (incidence rate [IR], 269 and 95 cases per 100,000 person-years, respectively) compared with matched control individuals (IR, 58 cases per 100,000 person-years; P < .001). Those with unclassified IBD and PSC had the highest risk for CRC (IR ratio [IRR], 7.38; 95% CI, 5.56-9.63). Compared with control individuals, patients diagnosed with IBD before the age of 20 years, with or without PSC, demonstrated a significantly elevated risk for CRC (IRR, 74.97 and 18.75, respectively; P < .001). CRC was more likely to be in the proximal colon among patients with IBD and PSC than among those with IBD without PSC and control individuals, with 37.5% vs 27% and 22.4% of CRC being located in the caecum and ascending colon. Synchronous cancers were found in 4.7% of patients with IBD and PSC and 4.4% of those with IBD without PSC vs 1.9% of control individuals (P < .001). Those with IBD and PSC had the highest mortality (adjusted hazard ratio, 2.56; P < .001). IN PRACTICE: "In PSC+ [IBD with a concomitant PSC diagnosis], primary CRC is more often located in the proximal colon. This must be considered when counselling patients with IBD regarding type of resection for cancer and choice of restorative surgery," the authors of the study wrote. SOURCE: This study was led by Maie Abdalla, MD, PhD, Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. It was published online on July 22, 2025, in Clinical Gastroenterology and Hepatology. LIMITATIONS: The register included only hospital discharge diagnoses before 2001, potentially missing outpatients with milder disease. Variables such as diet, smoking, family history of CRC, colitis severity, tumour stage, and others could not be accounted for. PSC lacks a specific International Classification of Diseases code; therefore, researchers had to combine a cholangitis code with an IBD diagnosis to identify cases. DISCLOSURES: This study was supported by the Medical Research Council of Southeast Sweden and by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement, Sweden. One author reported being an employee of AstraZeneca and having shares in the same. The author also reported receiving prior research funding and honoraria for lectures and consultancy from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Scoop
a day ago
- Health
- Scoop
Not Just A Baby In A Bin: Confronting Systemic Failure And Reproductive Injustice In Fiji
Fiji Women's Rights Movement (FWRM), as an organisation committed to gender equality and reproductive justice in Fiji, The International Planned Parenthood Federation (IPPF) a global healthcare provider and a leading advocate for sexual and reproductive health and rights (SRHR) in the region along with its Fiji Member Association (MA) - the Reproductive Family Health Association of Fiji (RFHAF), are outraged and deeply saddened by the discovery of a newborn baby boy abandoned in a sanitary bin inside the washroom of a tertiary institution's hostel in Lautoka. The infant, thankfully alive when found by a student after hearing his cries, was cared for by hostel staff and transferred to the hospital. This occurred in a place of learning, where young people should be safe and supported, is both shocking and heartbreaking. This incident must not be treated as a sensational story or isolated act of desperation. It is a clear and painful signal of multiple system failures – lack of access to safe and affordable sexual and reproductive health (SRH) services, in education, in public health outreach, and in how our society treats young women, especially when they are vulnerable and in crisis. From a feminist perspective, this is fundamentally an issue of reproductive justice. No woman or girl should feel so alone, unsupported, or afraid that she is left with no option but to abandon her newborn in secrecy and fear. Shame, stigma, and silence—particularly around unplanned pregnancy, sexuality, and reproductive decision-making—continue to control the lives of too many young women in Fiji. These conditions are created by patriarchal norms and worsened by a lack of access to accurate information, non-judgmental support, and safe, confidential services. Right to reproductive health continues to be controlled, policed, and politicised by the unjust systems. We are particularly concerned that this happened in a tertiary institution—spaces that should not only educate but protect. This highlights the urgent need to implement Comprehensive Sexuality Education (CSE) and to fully integrate it in our school curriculum including tertiary institutions. The absence of accessible counselling, reproductive health information, and emergency support options in such settings is unacceptable. Institutions must take immediate responsibility for ensuring students have somewhere safe to turn when in crisis. Without CSE, young people are left uninformed and unprepared, made more vulnerable to exploitation, unwanted pregnancy, and unsafe outcomes like this one. Fiji has ratified the Convention on the Rights of The Child (CRC) in 1993 whereby CRC strongly advocates for the realization of children's and adolescents' sexual and reproductive health and rights, urging states to ensure universal access to comprehensive SRH services and information. Fiji's youth have the right to access accurate, age-appropriate, evidence-based education on consent, contraception, reproductive choices, emotional relationships, and bodily autonomy. Denying them this knowledge is not only negligent—it is dangerous. We cannot continue to push for outdated 'abstinence-only' narrative when our young people are exploring their SRH. Sexual and reproductive health and rights are essential for achieving the Sustainable Development Goals (SDGs). Specific targets in Goal 3 (Good Health and Well-being) and Goal 5 (Gender Equality) directly focus on ensuring universal access to SRH services, family planning, information, and education, as well as integrating reproductive health into national strategies. Rather than respond with blame or punishment, we call for empathy, compassion, accountability, and reform. This must include a full and gender-sensitive investigation that respects the dignity and privacy of the woman involved. It is critical to create a safe and accessible spaces in healthcare settings that respect young women's individuals' autonomy and offer non-judgmental support. She is not the problem—our systems are. We must ensure tertiary institutions have clear, confidential pathways for students to access reproductive health services, counselling, and support before, during, and after pregnancy. These confidential and non-discriminatory services are offered by RFHAF in Suva and Sigatoka. Fiji must also explore options like anonymous safe-surrender mechanisms, supported by social services and health workers that give women in crisis a humane alternative. In parallel, we must strengthen public education to dismantle the stigma and shame that push women into isolation. This baby must now be protected, cared for, and given every chance at a healthy life—but we must also care for the mother. We cannot allow this tragedy to be repeated in silence. If we are serious about valuing life, we must be serious about supporting the lives of women and girls, too.
Arabian Business
2 days ago
- Business
- Arabian Business
Dubai real estate: Commercial property sales surge 50% to $8.4bn in Q2 2025
CRC Property has reported commercial property sales across Dubai reached AED 31 billion in the second quarter of 2025, marking a 50 per cent increase from the same period last year. The commercial real estate advisory firm's Q2 2025 Commercial Property Market Report shows transaction values rose from AED 20.75 billion in Q2 2024. The firm recorded a 75 per cent increase in sales deals year-on-year during what it describes as its most successful quarter to date. Behnam Bargh, Managing Director at CRC, said: 'Q2 2025 represents a defining moment for both CRC and Dubai's commercial landscape. We recorded our most successful quarter to date, with a 75 per cent increase in sales deals year-on-year. This is a direct result of our team's client-first approach and commitment to driving tangible value for our partners.' Dubai commercial property sales soar The office segment generated AED 2.62 billion in sales, representing a 93 per cent increase from Q2 2024. Transaction volumes increased by 26 per cent during the same period. Business Bay and Jumeirah Lake Towers maintained their positions as the most active areas, whilst Motor City and Barsha Heights showed increased activity. Off-plan office sales contributed a notable portion of transactions, with developments such as Omniyat's Lumena tower in Business Bay launching during the quarter. 'The success of off-plan reflects a maturing buyer mindset — long-term occupiers and institutional investors are committing to spaces that match tomorrow's needs, not just today's,' Bargh added. Warehouse sale prices averaged AED 22.2 million, up 107 per cent from Q2 2024. The increases stem from limited supply and demand for facilities in Dubai Industrial City, DIP and JAFZA. Transaction sizes have grown as logistics sector occupiers seek facilities to support regional operations. Leasing deals rose 30 per cent quarter-on-quarter, with office leasing prices averaging AED 480,768 — a 95 per cent increase year-on-year. The increases reflect demand for fitted office spaces in strategic locations. The report attributes the market performance to investor confidence, high-quality off-plan commercial developments, and demand for Grade A office and industrial assets.
Yahoo
3 days ago
- Business
- Yahoo
Is California Resource Company's 10% FCF Yield a Bargain or a Warning Sign?
When I evaluate a company, I don't think in terms of stock charts, quarterly earnings beats, or Wall Street narratives. I think about businesses. Specifically: Would I want to own 100% of this company at this price and hold it for the next 5-10 years? In that spirit, let's take a closer look at California Resources Corporation (CRC). It's an upstream oil and gas company operating in one of the most misunderstood marketsCalifornia. On the surface, this company produces oil. But beneath that, there's something else: a deeply undervalued asset base, durable cash flows, and an intriguing second enginecarbon capture and storagethat just might turn CRC into a long-term compounder hiding in plain sight. Warning! GuruFocus has detected 6 Warning Sign with LNG. CRC is not your typical shale operator. It holds long-life, conventional oil fields in the San Joaquin and Los Angeles Basins, including names like Elk Hills and Kern Front. These aren't high-decline, capital-hungry assets. These are slow-and-steady producers that have been pumping for decades and still have decades to go. As of year-end 2024, CRC reported 545 million barrels of oil equivalent in proved reserves, with over 80% in oil. That equates to nearly an 11-year reserve life, which is unusually long for an independent producer. Importantly, CRC owns its infrastructurepipelines, steam generation plants, even mineral rights in many of its operating areas. This vertical integration creates both operating efficiency and margin stability. And in a business where the price of the commodity can swing dramatically, any degree of cost control is a significant advantage. Think of it as owning not just the oil, but the entire value chain through which that oil flows. But oil isn't the only thing buried in CRC's asset base. Through a business unit called Carbon TerraVault, the company is turning depleted reservoirs into carbon storage sites. With the U.S. government now offering $85 per metric ton of CO? stored (under the 45Q tax credit), CRC has a shot at transforming geological leftovers into a regulated, cash-flowing service business. It's a free call option on energy transition infrastructureand few investors seem to be paying attention to it. CRC stands out as a rare case where the quality of the underlying assets is matched by the quality of its leadership. The business generates steady, durable cash flowsand management has shown a clear commitment to disciplined, shareholder-focused capital allocation. After emerging from Chapter 11 bankruptcy in 2020, CRC didn't go on a spending spree or chase high-risk growth. Instead, the company cleaned up its balance sheet, focused on capital discipline, and made a few smart movesmost notably, acquiring the remainder of Aera Energy, which came with synergistic cost reductions now expected to save the company $65 million annually. But the best evidence of management quality comes from how they treat shareholders. In Q1 2025 alone, CRC returned $258 million via dividends and share buybacks. That's over 6% of its market cap in just one quarter. In full-year 2024, around 85% of free cash flow was returned to shareholders. They're not trying to become Exxon or drill in far-flung frontiers. They're doing what I wish more public companies would do: generate surplus cash and give it back to the owners. If I can buy a dollar for fifty centsand the dollar is growingthat's a business I want to own. CRC generated around $355 million in free cash flow in 2024, and added another $131 million in Q1 2025, bringing its trailing 12-month free cash flow to over $450 million. Right now, its market capitalisation sits at roughly $4.2 billion. That gives the stock a free cash flow yield of approximately 10.7%, calculated as $450 million $4.2 billiona figure that speaks directly to the company's ability to return capital while remaining self-funded. When a company is throwing off this much cash relative to its sizeand returning most of it to shareholdersthat's the kind of setup worth paying attention to. It also trades cheaply at 4.2 times EV/EBITDA and only 8.2 times earnings. Now here's the kicker: CRC's proved reserves carry a PV-10 value of $8.9 billion, assuming around $80 Brent crude. That's nearly double the company's current enterprise value. This is what I call a real margin of safety. Even if you haircut the PV-10 by 25% to be conservative, the adjusted asset value still comes in well above the current stock price. And this doesn't account for the carbon business at all. If Carbon TerraVault becomes even a moderately successful carbon sequestration platform, that's hundreds of millions in future earnings being given away for free today. When insiders and seasoned investors make moves, I pay attention. James Chapman, the company's director, has been quietly increasing his stake. And he's not the only one leaning in. Howard Marks (Trades, Portfolio)' Oaktree Capital may have trimmed its stake, but still holds 1.38 million shareshardly a vote of no confidence. Jeremy Grantham (Trades, Portfolio) boosted his position by nearly 38%, now holding 1.22 million shares. Ken Griffin's Citadel ramped up its stake by over 90%, now sitting on 1.16 million shares. And Renaissance Technologies (Trades, Portfolio)? They more than doubled downraising their position by over 185% to more than 590,000 shares. The signal is clear: CRC isn't just cheap. It's attracting the kind of capital that tends to be earlyand usually right. Many investors avoid CRC for one reason: it operates in California. The Golden State's regulatory environment is tough on oil producers. Permitting is slow. Environmental opposition is fierce. And long-term state policy is tilted toward renewables. This California discount is realand it's precisely why CRC trades so cheaply relative to its assets. But what if that discount is backward-looking? CRC already operates under the strictest oil rules in the countryand still generates 10%+ free cash flow. Its assets are permitted. Its reservoirs are mature. It doesn't need to grow production. In fact, it's better off not growing, just maintaining stable output and maximizing returns. Ironically, California's aggressive climate stance may become a tailwind for CRC's carbon capture business. The same regulatory system that makes drilling difficult also supports carbon sequestration. With 45Q credits, state incentives, and access to industrial CO? emitters, CRC could end up being one of the most profitable climate infrastructure plays in the countryhidden inside an oil company. Of course, CRC isn't without risk. Oil prices are volatile, and CRC's earnings are sensitive to Brent crude. If prices fall to $50 or below, cash flows will compress. That's the nature of a commodity business. And while the CCS business is promising, it's still early. There's execution risk, regulatory complexity, and market uncertainty. Not every CCS project will succeedor scale profitably. But here's where CRC is different from speculative startups or over-leveraged E&Ps: even without CCS, it's a healthy business. Its existing oil fields, infrastructure, and free cash flow give investors a solid floor. The upside from CCS is just thatupside. The best use of capital is to reinvest at high rates of return. But if you can't do that, you should return it to shareholders. CRC appears to be doing both. It continues to invest modestly in CCS and other internal improvementsprojects with a clear path to economic return. At the same time, it is aggressively returning capital through buybacks and dividends. Unlike many in its industry, it's not chasing growth for growth's sake. That's rare. With net debt only $882 million and operating cash flows more than covering capex and dividends, this is a self-funding business that doesn't rely on capital markets or leverage to survive. That's a trait I value deeply. Let's put it all together. If I could buy CRC for $4 billion, I'd be acquiring: Nearly $9 billion in PV-10 value of proved reserves (even more if oil prices stay strong). A carbon storage platform with substantial optionality and favorable federal tax incentives. A vertically integrated infrastructure network that lowers operating costs. A management team that acts like owners and returns cash instead of hoarding it. Even with conservative assumptionshaircutting reserve values and assuming zero value for CCSCRC still looks like a business selling at a 3040% discount to intrinsic value. Add in the fact that shareholders are being paid over 10% annually in cash while they wait, and it's hard not to see the appeal. Warren Buffett (Trades, Portfolio) once said: Price is what you pay, value is what you get. In CRC's case, the price is modest. The value is real. And the optionality is free. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
